Neuroendocrine gastroenteropancreatic tumors (GEP-NETs) constitute a heterogeneous group of tumors with their origin in neuroendocrine cells of the embryological gut. This guideline focuses on diagnosis and pathology/molecular biology...
The aim of this study was to collect ALK IHC+ cases and compare within this group response to crizotinib treatment of ALK FISH+ cases with ALK FISH- cases.
Background: Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors.
Nexavar (sorafenib tosylate), from Bayer HealthCare, was effective in patients with Non-Small Cell Lung Cancer and a KRAS mutation, but...
We aimed to assess the safety and efficacy of efgartigimod (ARGX-113), a human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG autoantibody levels, in patients with generalised myasthenia gravis.
Objective: To construct biomarker-based prognostic models that enable determination of future AD dementia in patients with MCI.
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
We aimed to investigate which retinal layers show atrophy associated with neurodegeneration in multiple sclerosis when measured with SD-OCT.
Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective (see section 4.2). Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome (see section 5.1). Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded. Treatment of TSH-secreting pituitary adenomas: • when secretion has not normalised after surgery and/or radiotherapy; • in patients in whom surgery is inappropriate; • in irradiated patients, until radiotherapy is effective.